ABSTRACT
Objective To observe and compare the effect of Cordyceps sinensis ( bailing ) capsules com-bined with weight-bearing breathing exercises, and weight-bearing breathing exercises combined with tiotropium bro-mide and seretide, on patients with stable but moderate-to-severe chronic obstructive pulmonary disease (COPD). Methods Sixty-three patients with moderate-to-severe COPD were randomly divided into an observation group and a control group. Both groups performed weight-bearing breathing exercises, supplemented in the observation group with the oral administration of bailing capsules. The control group instead inhaled tiotropium bromide and seretide. Six-mi-nute walking distance, the COPD assessment test ( CAT scores) and concentrations of interleukin-6 ( IL-6) , interleu-kin-8 ( IL-8) and tumor necrosis factor-α ( TNF-α) were observed after 1 ( T1) , 30 ( T2) and 58 ( T3) days of the treatments. Results At T1 there were no significant differences between the two groups in any of the measurements ( P≤0.05) . At T2, there were still no significant differences except that a significant decrease in IL-8 and TNF-αlevels was observed in the control group. At T3 the average CAT scores had decreased significantly in both groups compared to before the treatment but there was no significant difference between the two groups. In the observation group, the average 6MWT distance had increased significantly compared to before the treatment and compared to the control group, where there was no significant improvement. The average IL-6, IL-8 and TNF-αreadings of the control group were significantly lower than those of the observation group at T3 and compared to before the treatment. No sig-nificant changes in those indicators were observed in the observation group at T3. Conclusions Bailing capsules combined with weight-breathing exercises are more effective for relieving dyspnea symptoms and improving exercise capacity than weight-breathing exercises combined with tiotropium bromide and seretide. However, in controlling air-way inflammation and airway hyper-responsiveness, the triple inhalation combined with weight-bearing breathing exer-cises is more effective.
ABSTRACT
Objective To observe the effect of Fufei Gushen Decoction on the BODE index, an index for body mass index(BMI), airflow obstruction, dyspnea, and exercise capacity, in severe and extremely severe chronic obstructive pulmonary disease (COPD) patients with lung-kidney deficiency interweaved with phlegm and blood stasis at stable stage. Methods Eighty qualified COPD patients were randomly divided into treatment group and control group, 40 cases in each group. Both groups were given inhalation of Seretide (Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation) , and the treatment group was given oral use of Fufei Gushen Decoction additionally. The treatment for the two groups lasted for 3 months. Before and after treatment, BMI, the percentage of forced expiratory volume in one second of the predicted value (FEV1%) , dyspnea index of modified British Medical Research Council (MMRC), and exercise performance index of 6-min walking test (6MWT) in the two groups were observed. Results (1) After treatment, FEV1%, MMRC dyspnea index, 6MWT scores and BODE index overall scores of severe and extremely severe patients in the treatment group were much improved(P 0.05). MMRC dyspnea index, 6MWT scores and BODE index overall scores of severe and extremely severe patients inthe control group were much improved (P 0.05).(2) Except for BMI, the parameters of FEV1%, MMRC dyspnea index, 6MWT scores and BODE index overall scores of the treatment group were much improved as compared with those of the control group after treatment(P < 0.05). Conclusion Fufei Gushen Decoction combined with inhalation of Seretide exerts certain effects on decreasing the BODE index scores, relieving symptoms, and improving pulmonary function, exercise performance and the quality of life of COPD patients with lung-kidney deficiency interweaved with phlegm and blood stasis at stable stage.
ABSTRACT
Objective To study the effect improvation of lung function and prognosis of singulair and seretide for moderate to severe AECOPD . Methods 78 patients associated with moderate to severe AECOPD from January 2014 to June 2016 in our hospital were researched.They were divided randomly into observation and control groups according to the order of admission, 39 cases in each group.In the control group, they were treated by conventional anti-infective, expectorant, oxygen, suction seretide.In the observation group, using singulair on the basis of the control group.Clinical data, clinical efficacy, clinical symptoms begin to improve time, hospitalization time, blood gas analysis (PaO2, PaCO2) after five days and pulmonary function after treatment forced expiratory volume in one second ( FEV1 ) , call gas peak velocity ( PEF) , forced expiratory volume in one second than the forced vital capacity (FEV1/FVC), maximum mid-expiratory flow rate (MMEF) were compared with each other.Results Their clinical data of patients and other general information and basic condition had no significant difference between each other.The effective rate of observation group and control group were 97.44%and 87.18%, clinical effecicy of observation group was better than the control group, the difference was statistically significant (u=2.2805, P<0.05).Postoperative hospital stay, time of symptoms began to improve of the observation group were shorter than the control group, the difference was statistically significant (P<0.05), PaO2 of 5-day post-treatment of observation group was higher, and PaCO2 was lower, the difference was statistically significant (P<0.05).Lung function of two groups of patients had no significant difference before treatment, after treatment, pulmonary function in the observation group (including FEV1, PEF, FEV1/FVC, MMEF) was better than the control group, the difference was statistically significant (P<0.05).Conclusion Seretide combined with singulair to treat severe AECOPD has a good effect, it can significantly improve the therapeutic effect and improve the patient's lung function.
ABSTRACT
Objective:To analyze the clinical efficacy of Seretide combined with noninvasive positive pressure ventilation (NIPPV) in the treatment of chronic obstructive pulmonary disease (COPD) complicated with type 2 respiratory failure (RF).Methods:120 patients of COPD complicated with type 2 RF were randomly divided into the observation group and the control group.All patients were treated with routine,symptomatic and supportive treatment,based on that NIPPV was used in the control group,and the observation group was treated with Seretide on the basis of NIPPV.The levels of arterial blood gas,inflammatory factors,pulmonary function and CAPS score before and after treatment were compared and analyzed.Results:After treatment,the pH,PaO2 and SaO2 of both groups were significantly increased,PaCO2 levels weresignificantly decreased,serum IL-33,TNF-oα and sICAM-1 levels were significantly decreased,FVC,PEFR,FEV1％ and FEV1/FVC were significantly decreased,and the CAPS scores were significantly decreased;the changes of all the index mentioned above in the observation group were more statistically significant (P＜0.05).Conclusion:Seretide com bined with NIPPV could more effectively decrease the levels of inflammatory factors and improve the blood gas and lung function in the patients of COPD with type 2 respiratory failure.
ABSTRACT
ObjectiveTo explore the Clinical effect of Tiotropium Bromide combined with seretide in patients with chronic obstructive pulmonary disease at stable period.Methods84 patients with stable COPD from March 2015 to February 2016 in our hospital outpatient respiratory department were randomly divided into control group and treatment group.The control group was treated with Seretide, the treatment group was treated withtiotropium bromide on the basis of control group.Compared the lung function, blood gas analysis, 6-minute walking distance, dyspnea score and quality of life were between the two groups after six months of treatment.ResultsFVC, FEV1and FEV1/ FVC (%) in the treatment group were significantly higher than those in the control group (P<0.05).The score of quality of life and dyspnea in the treatment group were significantly lower than those in the control group (P<0.05).The 6MWD in treatment group was significantly longer than that in control group (P<0.05).PaCO2 was significantly lower in the treatment group than that in the control group, but PaO2 was significantly higher than that in the control group after six months treated(P<0.05).ConclusionThe combination of tiotropium bromide and seretide in patients with chronic obstructive pulmonary disease (COPD) is effective in improving pulmonary function, improving life therapy, and reducing the symptoms of dyspnea.
ABSTRACT
Objective To observe the effect of tiotropium combined Seretide in the treatment of elderly patients with moderate to severe COPD clinical curative effect and the influence on the quality of life of patients.Methods114 cases of moderate or severe COPD in our hospital from January 2014 to January 2016,were randomly divided into observation group and control group, 57 cases in each group.The control group was treated with Seretide treatment, the observation group were treated by tiotropium combined with Seretide treatment, compared two groups of patients with curative effect and quality of life.ResultsBefore treatment, there were no significant differences in lung function index, MRC score, 6MWT and WHOQOL-100 scores between the two groups;After treatment, FEV1/FVC and FEV1% in the observation group were significantly higher than in the control group, and the difference was statistically significant (P<0.05);the dyspnea severity score (MRC) and six minute walk test (6MWT) in the observation group were significantly better than those in the control group, and the differences were statistically significant (P<0.05);the quality of life score (WHOQOL-100) in the observation group was significantly higher than in the control group, the difference was statistically significant (P<0.05).ConclusionTiotropium bromide combined with nimesulide in the treatment of elderly patients with moderate or severe COPD is effective, and can effectively improve the level of pulmonary function, improve the quality of life of patients.
ABSTRACT
Objective To detect the immunoregulation and clinical effect ofYupingfeng capsule combined with Seretide on patients with cough variant asthma (CVA).Methods CVA Patients were randomly divided into the Seretide control group (n=54) andYupingfeng capsule combined with Seretide group (n=54). Seretide group received inhaled Seretide. Combined traditional Chinese medicine group received Seretide and Yuping Feng capsule. Two groups were treated for 12 weeks. The IL-17, IL-10 and IL-6 expression was detected by ELISA analysis. The clinic effect rate and adverse events were compared.Results After treatment, compared with the Seretide group, the expression of IL-17 (18.72 ± 4.26 ng/mlvs. 26.17 ± 5.58 ng/ml;t=2.462,P<0.05) and IL-6 (21.58 ± 4.12 ng/mlvs. 30.66 ± 6.27 ng/ml;t=2.523,P<0.05) were significantly lower in combined traditional Chinese medicine group than that in Seretide group; and IL-10 (15.56 ± 2.74 ng/mlvs. 12.25 ± 2.81 ng/ml;t=2.244, P<0.05) was significantly higher in combined traditional Chinese medicine group. The daytime (1.12 ± 0.26 vs.1.42 ± 0.33,t=2.283) and night time cough score (1.24 ± 0.28vs. 1.52 ± 0.37,t=2.291) in combined traditional Chinese medicine group was significantly lower than that in Seretide group (P<0.05). The clinic effect rate (92.6%vs. 77.8%,χ2=2.438) in combined traditional Chinese medicine group was significantly higher than that in Seretide group (P=0.037).ConclusionYupingfengcapsule combined with Seretide can decrease IL-17 expression and increase IL-10 expression to inhibit inflammatory reaction in CVA patients, and showed significantly higher clinical effect rates.
ABSTRACT
Objective To observe the clinical efficacy of Seretide combined withShiwei Longdanhua Granule in the treatment of chronic asthma duration.Methods Totally 110 patients with chronic asthma duration were randomly divided into treatment group and control group, 55 cases in each group. They inhaled Seretide 50/250μg, once in morning and evening, as a basic treatment. The treatment group was treated combined with oralShiwei Longdanhua Granule, 1 package each time, 3 times a day. The control group was treated combined with oral compound Methoxyphenamine, 2 capsules each time, 3 times a day. The course lasted for 7 days. The clinical symptoms, physical signs and the distance of 6-minute walk of the two groups were observed. Results After treatment, the clinical symptoms, physical signs and the distance of 6-minute walk of the two groups improved, without statistical significance between the two groups (P>0.05). Conclusion Inhaled Seretide combined with oralShiwei Longdanhua Granule for short period can improve the clinical syndromes and the distance of 6-minute walk, without statistical significance with Seretide combined with oral Methoxyphenamine.
ABSTRACT
Objective To evaluate the effect of montelukast combined with seretide in treatment of patients with asthma and its influence on balance between Th17 and Treg cells, and expression of IL-4 and IFN-γ.Methods 110 patients with asthma were randomly divided into observation group and control group, observation group of 55 cases, using montelukast combined with seretide, control group of 55 cases, using seretide,compared two groups of patients with pulmonary function changes, peripheral inflammatory factor changes and influence on Th17 and Treg cells balance. Results Before treatment, observation group and control group,FEV1 and FEV1 /FVC value was no significant difference.FEV1 and FEV1 /FVC after treatment were significantly improved compared with before treatment in two groups, differences were statistically significance (P<0.05).Between two groups, FEV1 values were significantly difference (t=8.1156, P=0.0001), FEV1 /FVC also had significant difference (t=4.8933, P=0.0001) .Before treatment, observation group and control group, IL-4 and IFN-γdid not have a statistically significant.After treatment, IL-4 and IFN-γdecreased significantly, with statistical difference compared with before treatment (P<0.05).Between two groups, IL-4 had significant difference (t=6.0273, P=0.0001), IFN-γalso had statistically significant (t=6.6042, P=0.0001).Before treatment, there was no significant difference between Th17 and Treg percentage, after 12 weeks of treatment and 24 weeks, Th17 in observation group were(0.53 ±0.02),(0.32 ±0.01), the control group were (0.78 ±0.03),(0.62 ±0.02), which had differences (P<0.05).After 12 weeks and 24 weeks,observation group Treg respectively(2.21 ± 0.22),(2.47 ±0.10),in control group were(1.50 ±0.11),(1.84 ±0.14), Treg percentage at different time after treatment, the differences had statistically significant (P<0.05).Conclusion Montelukast combined with Seretide in treating with asthma, pulmonary function of patients is obviously improved, and it can improve Th17, Treg cell.
ABSTRACT
Objective To investigate the clinical effect of tiotropium bromide combined with Seretide in treatment of moderate to severe chronic obstructive pulmonary disease( COPD) patients. Methods From Jan. 2012 to Oct. 2013,76 severe COPD were selected as our subjects and they were randomly divided into the control group(38 cases)and research group(38 cases). Patients in control group were used Seretide(1 time both at morning and night,the does was 50 μg/ 500 μg),and in research group were given tiotropium bromide with thiophene beside Seretide(1 time every day). The two groups were received routine treatment,including anti infection,cough and asthma,according to the change of illness. The pulmonary function,blood gas index, respiratory symptoms and 6 minutes walking distance(6 MWD)were recorded. Results Forced expiratory volume in one second( FEV1),forced vital capacity( FCV),FEV1 / FCV of patients in research group after ftreatment were(2. 22 ± 0. 48)L,(3. 28 ± 0. 32)L,(66. 23 ± 9. 22)% respectively,higher than those in the control group,and the differences were significant((1. 78 ± 0. 35)L,(2. 85 ± 0. 47)L,(56. 83 ± 7. 85)% ;t= 5. 39,4. 66,4. 78;P < 0. 01). Partial pressure oxygen(PaO2 )of patients in research group after treatment was (72. 83 ± 5. 28)mmHg,significantly higher than that of control group((65. 36 ± 3. 22)mmHg). However, partial pressure of carbon dioxide( PaCO2 )was(43. 28 ± 3. 52)mmHg,significantly lower than the control group((48. 76 ± 2. 85)mmHg;t = 7. 44,7. 45,P < 0. 01). Dyspnea( MMRC)score in research group was (1. 38 ± 0. 32),lower than the control group(1. 76 ± 0. 35),and 6 MWD was(428. 36 ± 32. 85)m,higher than that of control group((398. 65 ± 28. 38)m;t = 4. 93,4. 21,P < 0. 01). Conclusion The treatment plan of tiotropium bromide combine with Seretide on moderate and severe COPD patients is proved with the better clinical effect and it can improve the partial pressure of oxygen and then promote repair mechanism of lung injury as well as promote the quality of life of patients with ascension.
ABSTRACT
Objective To investigate the effect of Bi-level positive airway pressure ventilation (BiPAP) combined with Seretide on quality of life of elder patients with moderate and severe chronic obstructive pulmonary disease (COPD) and type Ⅱ respiratory failure.Methods Eighty elderly patients with moderate to severe COPD and type Ⅱ respiratory failure were selected and randomly divided into observation group (n =40) and control group(n =40).The two groups were given conventional anti infection,oxygen inhalation,spasmolysis,expectorantand other conventional treatment,and the use of BiPAP ventilator assisted ventilation.Patients in observation group were administered the combined of Seretide and BiPAP treatment,and patients in control were received only BiPAP.Arterial blood gases before and after 7 d treatment,lung function and quality of life evaluation results (SQGR score) before and after 7 d,3 months and 6 months treatment,were measured.Results There were significant differences in terms of arterial blood gases,pulmonary function key indicators,SQGR score between two groups before and after treatment(P ＜ 0.01).PaCO2 was significantly after 7 d of treatment in observed group was (42.9 ± 7.9) mmHg,lower than that of the control group ((47.6 ± 8.0) mmHg; t =8.467,P ＜0.001).There was no significant difference in terms of forced expiratory volume in one second(FEV1) in both groups at 7 d,3 months,6 months after treatment (P ＞ 0.05).FEV1/forced vital capacity (FVC) in two group at 3 months,6 months after treatment were different compared to 7 d after treatment (observation group:(49.9 ±5.1)％ and (47.1 ±4.2)％,(50.2 ± 5.0)％ and(47.1 ±4.2)％ ;control group:(49.0 ± 5.4)％and (46.6 ± 5.9) ％,(49.8 ± 5.2) ％ and (46.6 ± 5.9) ％ ; P ＜ 0.05).SQGR score in observation group at six months after treatment were (40.8 ± 8.5),significantly lower than that of 7 d after treatment(45.9 ± 10.8),P ＜ 0.05),and significantly lower than the control group after 6 months of treatment ((40.8 ± 8.5) vs (46.0± ± 8.0),P ＜ 0.05).Conclusion Seretide combined with BiPAP treatment can significant improve lung function and the quality of life of patients with moderate and severe COPD and type Ⅱ respiratory failure.
ABSTRACT
Objective To explore the effects of seretide (salmeterol 50 μg and fluticasone propionate 500 μg) on lower airway bacterial colonization (LABC) in the patients with stable moderate-tosevere chronic obstructive pulmonary disease (COPD).Methods A total of 84 patients with moderate-tosevere COPD were divided into 2 groups,i.e.test (n =43) and control (n =41).The control group received basic treatment while the test group seretide 50/500 μg per inhalation twice daily for 2 years plus basic treatment.Induced sputum specimens were analyzed for quantitative bacteriology and bacterial culture.The pulmonary function key parameters and exacerbation frequency were compared between two groups at pre- and post-therapy.Results The test group has significantly a lower positive rate of bacterial culture in the lower respiratory tract than before(16.3％ vs.34.9％,x2 =3.9091,P =0.0480).While in the control group,the positive rate of bacterial culture stayed almost the same as compared with that at pre-therapy (x2 =0.2253,P =0.6350).The test group had significantly decreased exacerbation frequency than the control group (1.9±2.1 vs.2.9 ±2.3,t =2.0364,P =0.0449);FEV1 of the control group decreased by (0.0885 ± 0.0186)L in 2 years and decreased by (0.0807 ± 0.0165)L in the test group.Significant differences existed in two groups (t =2.0355,P =0.0450).Conclusion The treatment of seretide can decrease LABC,slow decreasing trend of lung function and improve clinical symptoms in the patients with stable moderate-to-severe COPD.
ABSTRACT
Objective To explore the effects of Seretide(50/250 μg)in the treatment of patients with stable moderate COPD.Methods Sixty-four patients in the stable period of moderate COPD were randomized into 2 groups,the test group and control group.The control group received routine treatment.The test group received the Seretide(50/250 μg)inhalation in addition to the routine treatment.During the 2-year observation,the pulmonary functions before and 12 and 24 months after treatment were recorded.The clinical symptoms,physical signs,the frequency of acute exacerbation of COPD and hospitaliztion duration were also graded.Results The difference of the parameters before and after the treatment was significant in the treatment group(P ＜0.01)but not in control group(P ＞0.05).The scores of symptoms and signs([2.1 ±0.4]vs.[4.4 ± 0.3],t =2.365),the frequency of acute exacerbation of COPD(29％ vs.47％,x2 =3.547)and hospitalization period ([5.0 ± 1.2]d vs.[10.0 ± 1.6]d,t =2.149)in the treatment group were significantly improved compared with control group after 24 months' treatment(all P ＜ 0.01).Conclusion Seretide(50/250 μg)is able to improve the lung function of the patients with stable moderate COPD and reduce the frequency of acute exacerbation,showing certain value in clinical practice.
ABSTRACT
Objective To observe effect of corticosteroid and long-acting ?2-agonist seretide to treat patients with moderate asthma who were uncontrolled on existing corticosteroid therapy.Methods From Oct.2005 to Feb.2007,85 asthmatic patients were randomly divided into two groups,treatment group were treated with seretide twice daily and the control group were treated with pulmicort(budesonide)twice daily.The clinical effect index and peak expiratory flow(PEF)were analyzed statistically.Results There were 61 cases in seretide group and 24 cases in pulmicort group who were follow-up examined and evaluated effectively the clinical effect.The treatment period was 1 year,the efficacy were 100% and 75% respectively,there was significant difference between two groups(P